Malvern Panalytical Acquired Dimer Instruments
The biotech firm will integrate the Santa Barbara-based company to enhance protein stability screening and drug development.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that corporate mergers typically lead to better products for the consumer?
Malvern Panalytical has completed the acquisition of Dimer Instruments following a minority investment earlier this year. The deal aims to accelerate innovation in biopharmaceutical research and protein stability screening.
Why it matters
The acquisition combines Dimer Instruments specialized research with Malvern Panalytical broader scientific expertise and global distribution. This partnership focuses on advancing new technologies to support biopharmaceutical customers in drug development.
The Dimer Instruments Zetasizer Core platform supports particle analysis using 96-, 384-, and 1536-well plates. This system integrates dynamic light scattering, static light scattering, and differential scanning fluorimetry in a single workflow.
The players
Malvern Panalytical
A global analytical instrumentation company formed in 2017 that specializes in materials and biophysical characterization.
Dimer Instruments
A Santa Barbara-based developer of high-throughput biophysical characterization tools used in pharmaceutical research.
Stephen Minne
A co-founder of Dimer Instruments who helped establish the company in Santa Barbara.
Michael Larkin
A co-founder of Dimer Instruments who contributed to the development of the firm's core light scattering technologies.
The details
The integration leverages Dimer scientific research capabilities alongside Malvern Panalytical existing infrastructure. This move allows for the expansion of specialized biopharmaceutical tools capable of high-throughput analysis.
Timeline
Late 1960s marked the origins of Malvern Instruments.
2017 saw the formal merger of Malvern Instruments and PANalytical.
April 2024 was when the initial minority investment in Dimer took place.
September 2026 was the launch date of the Zetasizer Core platform.
October 2026 is when the acquisition was officially announced.
The Tech Race
The acquisition of Dimer Instruments marks a significant consolidation in the market for high-throughput protein stability analysis tools. By absorbing this technology, Malvern Panalytical positions itself to compete more aggressively against firms streamlining early-stage drug discovery pipelines.
Biopharmaceutical researchers can expect enhanced access to integrated screening workflows through Malvern Panalytical expanded distribution networks. This consolidation may lead to faster adoption of the Zetasizer Core platform in labs looking to improve the efficiency of drug development workflows.
The takeaway
This acquisition highlights how established analytical firms are increasingly turning to specialized startups to integrate sophisticated, high-throughput research tools into their portfolios. Biotech companies should monitor how this integration impacts the availability and technical support for advanced light scattering platforms.
Further reading
For more on industry shifts, visit the Biotech section.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Do you trust that corporate mergers typically lead to better products for the consumer?
